A phase II study with perioperative modified docetaxel, cisplatin, and capecitabine (mDCX) in resectable gastroesophageal adenocarcinoma.

Fonseca, Paula; Vieitez, José María; Turienzo, E.; Sanz, Lourdes; Pérez, Guillermo J.; Izquierdo, M.; Pardo-Coto, P.; Frunza, M.; Restrepo, Eduardo Gutierrez; Lacave, A.J.

doi:10.1200/jco.2011.29.15_suppl.e14554

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one study evaluated a regimen containing 5-Fluorodeoxyuridine 24 . Ten studies evaluated DCF and its modifications 9–11,17,18,20,21,25–27 .…”

Section: Resultsmentioning

confidence: 99%

“…The DCF regimen had previously demonstrated to be superior to the two-drug regimens, but in a metastatic disease scenario, in V325 study 30 . Regimen modifications concerning tolerability and toxicity issues were extensively studied with apparently similar results although there is no direct comparison between them 9–11,17,18,20,21,25–27 . When analyzing the rates of complete pathological response in the various docetaxel regimens including FLOT and modified DCF regimens, we can see that there is great similarity between the regimens and their efficacy (0.13; 95% confidence interval [CI], [0.1; 0.16]) heterogeneity (I2 = 23%).…”

Section: Discussionmentioning

confidence: 99%

“…As it is expected, regimens that contemplate oxaliplatin present higher rates of neurosensory toxicities, sometimes irreversible, and platinum-based treatments frequently contemplate hematological toxicities. Regarding the use of fluoropyrimidines apparently the use of oral fluoropyrimidines is more toxic, including capecitabine and S1, a possible cause may be related to increased exposure time to the chemotherapeutic agent when compared to periodic infusions, differences related to frequency of laboratories in the trials and lower tolerability in Caucasian patients 25,26,37,38 . Our analysis raised the studies that used regimens with infusional fluorouracil, they were better tolerated, in addition, infused fluorouracil in more than 24 hours apparently is also better tolerated.…”

Section: Discussionmentioning

confidence: 99%

“…(FLOT 4 Phase III) 6 2017Western EuropeProspective356≥T2 or N+Gastric, GEJ43FLOT200D2NR84241(67.6)297 (83)242(68)Fonseca et al . 25 2011Western EuropeProspective26T3, T4 or N+Gastric, GEJ, DENRDCX210NR9NRNRNRNRThuss-Patience et al . 26 2012Western EuropeProspective51T3, T4 or N+Gastric, GEJ, DE24.8DCX225D213.79041(80)44(88)36(70.8)Ferri et al .…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors

Usón

Santos

Bugano

et al. 2019

Sci Rep

View full text Add to dashboard Cite

FLOT regimen became the standard perioperative treatment in several centers around the world for esophagogastric tumors despite concerns about toxicity. In addition, FLOT has never been compared with other docetaxel-based regimens. To address this question, we conducted a systematic review of PubMed, Embase and Web of Science including prospective or retrospective studies of docetaxel based perioperative regimen in gastric and esophagogastric tumors. Data regarding chemotherapy regimens, efficacy and toxicity were extracted. Outcomes were compared using a random effects model. Of 548 abstracts, 16 were considered eligible. Comparing the studies with meta-analysis we can see that the regimens are similar in terms of pathological complete response, resection rate, progression free survival and overall survival in one year, without significant heterogeneity. The meta-regression of docetaxel dose failed to show any association with dose ranging between 120–450 mg/m². Regarding the toxicity of the regimens it is noted that the regimens are quite toxic (up to 50–70% of grade 3–4 neutropenia). The results of this meta-analysis with a combined sample size of more than 1,000 patients suggest that docetaxel perioperative regimens are equivalent in outcomes. Prospective trials addressing modified regimens should be performed to provide less toxic strategies and be applicable to all patients.

show abstract

“…Only one study evaluated a regimen containing 5-Fluorodeoxyuridine 24 . Ten studies evaluated DCF and its modifications 9–11,17,18,20,21,25–27 .…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors

Usón

Santos

Bugano

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Likewise the addition of docetaxel to cisplatin and 5-FU (DCF) was found to be well tolerated with a pCR rate of 47%, a 3 year survival of 81% (Pasini et al, 2009 ), and an overall response of 60% (Hara et al, 2011 ). Adding docetaxel to cisplatin and capecitabine (DCX) also resulted in tumor downstaging in 56% of patients (Fonseca et al, 2011 ) and successful R0 resection in 90% of patients (Thuss-Patience et al, 2011 ). Furthermore, many trials had compared the efficacy of different chemotherapy combinations.…”

Section: Treatment Of Locally Advanced Esophageal Cancermentioning

confidence: 99%

Locally Advanced Cancer of the Esophagus, Current Treatment Strategies, and Future Directions

Rahma¹,

Greten²,

Duffy³

2012

Front. Oncol.

View full text Add to dashboard Cite

For patients with locally advanced esophageal cancer no clear standard of care exists. Notwithstanding several negative phase III studies the data provide support for so-called trimodality treatment and this is probably the most common approach. Even the role of surgery has been questioned. These alternative approaches are set against a changing epidemiological background whereby adenocarcinoma has become the predominant tumor type, at least in the western world. In recent times an emphasis has been placed on the better selection of patients, predominantly based on data that shows a markedly improved survival in those who exhibit a response to neo-adjuvant therapy. In this article we review the major studies and discuss new approaches to the management of patients with locally advanced cancer of the esophagus.

show abstract

A phase II study with perioperative modified docetaxel, cisplatin, and capecitabine (mDCX) in resectable gastroesophageal adenocarcinoma.

Cited by 2 publications

References 0 publications

Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors

Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors

Locally Advanced Cancer of the Esophagus, Current Treatment Strategies, and Future Directions

Contact Info

Product

Resources

About